FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	OMB APP	PROVAL
CLUD	OMB Number:	3235

OMB Number:	3235-0287
Estimated average burd	den
hours per response:	0.5

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  FORMELA JEAN FRANCOIS  (Last) (First) (Middle)  C/O SPERO THERAPEUTICS, INC.  675 MASSACHUSETTS AVENUE, 14TH FLOOR  (Street)  CAMBRIDGE MA 02139					2. Issuer Name and Ticker or Trading Symbol Spero Therapeutics, Inc. [SPRO]  3. Date of Earliest Transaction (Month/Day/Year) 08/17/2021  4. If Amendment, Date of Original Filed (Month/Day/Year)								heck all X C C t Individue) X F					plicable
(City) (State) (Zip)  Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)			ction 2A. Deemed Execution Date,		3. Transac Code (II 8)	ction	4. Securi	ities Acquir d Of (D) (Ins (A) o	ed (A) or str. 3, 4 an	5. Amount of Securities Beneficially Owned Follow Reported		s Form (D) or ollowing (I) (In:		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution D if any (Month/Day/	ution Date, Tr		saction le (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		tive ties red sed 3, 4	6. Date Exe Expiration (Month/Day Date Exercisable	Date y/Year		7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)  Amount or Numl of Title Share		ount ober		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	i ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy) \$13.69	08/17/2021			A		7,500	.,	(1)	08	3/17/2031	Common Stock	7,500	\$0.	.00	7,500		D <sup>(2)</sup>	

#### **Explanation of Responses:**

- 1. The shares underlying this option will vest and become exercisable in full on August 17, 2022 subject to the Reporting Person's continued service as a director through the vesting date.
- 2. The reporting person is a member of Atlas Venture Associates IX, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to Atlas Venture Advisors, L.P. As such, the Reporting Person disclaims beneficial ownership to the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

## Remarks:

/s/ Matthew J. Gardella, as Attorney-in-Fact for Jean Francois Formela

08/18/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.